Mercaptopurine oral suspension

Drug Profile

Mercaptopurine oral suspension

Alternative Names: Allmercap; Purixan; Xaluprine

Latest Information Update: 24 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nova Laboratories
  • Class Antineoplastics; Purines; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 08 Apr 2015 The product is approved for Acute lymphoblastic leukaemia in European Union
  • 18 Feb 2015 Launched for Acute lymphoblastic leukaemia in USA and Czech Republic (PO) prior to February 2015
  • 17 Jun 2014 Mercaptopurine oral suspension licensed to LINK Healthcare in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top